How much funding has Gentibio raised?

Gentibio has raised $177.0M in total funding, most recently a Series A round.

Who are Gentibio's investors?

Gentibio's investors include OrbiMed, Matrix Capital Management, Avidity Partners, Novartis Venture Fund, RA Capital Management.

Where is Gentibio headquartered?

Gentibio is headquartered in Cambridge.

What industry is Gentibio in?

Gentibio operates in Biotech, Healthcare.

Gentibio

Cambridge · Founded 2020 · $177.0M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 51–200
Founded: 2020
Business Model: B2B

Website: gentibio.com
Total Funding: $177.0M
Last Round: $157.0M Series AAug 2021
Rounds: 2

About

GentiBio is a clinical-stage biotechnology company developing engineered regulatory T-cell (Treg) therapies to treat Type 1 diabetes and other autoimmune and acute inflammatory diseases. The company's modular engineering platform creates optimized Tregs with immune-evasive properties for both autologous and allogeneic approaches, advancing multiple programs through clinical trials toward potential cures.

Summary

Gentibio is a Biotech company based in Cambridge, founded in 2020. It has raised $177.0M in total across 2 rounds, most recently a $157.0M Series A round in Aug 2021. Investors include OrbiMed, Matrix Capital Management and Avidity Partners.

LinkedIn X (Twitter)